Ginkgo Bioworks (DNA) Set to Announce Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $21.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.15. The firm had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $24.05 million. Ginkgo Bioworks had a negative net margin of 259.96% and a negative return on equity of 60.27%. On average, analysts expect Ginkgo Bioworks to post ($3.20) EPS for the current fiscal year and ($2.90) EPS for the next fiscal year.

Ginkgo Bioworks Price Performance

NYSE DNA opened at $10.74 on Wednesday. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $18.22. The business’s 50-day moving average is $9.68 and its 200 day moving average is $8.59.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Zacks Research upgraded Ginkgo Bioworks to a “hold” rating in a research report on Monday, August 17th. BTIG Research reaffirmed a “sell” rating and issued a $5.00 price target on shares of Ginkgo Bioworks in a research note on Friday, September 4th. TD Cowen lifted their price target on shares of Ginkgo Bioworks from $9.00 to $11.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Thursday, October 15th. Finally, Oppenheimer set a $5.00 price objective on shares of Ginkgo Bioworks in a report on Wednesday, September 9th. Two investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $7.00.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Steven Coen sold 2,403 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $15.00, for a total transaction of $36,045.00. Following the sale, the insider owned 49,448 shares in the company, valued at approximately $741,720. The trade was a 4.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Reshma Shetty sold 22,369 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $10.14, for a total transaction of $226,821.66. Following the completion of the sale, the insider directly owned 453,951 shares in the company, valued at $4,603,063.14. This represents a 4.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 136,525 shares of company stock valued at $1,379,699. Company insiders own 12.69% of the company’s stock.

About Ginkgo Bioworks

Ginkgo Bioworks is a biotechnology company that develops and deploys biological systems for commercial and industrial applications. Its platform is designed to help customers program cells to produce a wide range of products, including pharmaceuticals, food ingredients, agricultural inputs, specialty chemicals and materials. The company combines biological engineering, automation, software and data science to design, build and test engineered organisms.

Ginkgo provides services through its cell-programming platform and biological engineering foundry, supporting activities such as genetic design, strain construction, laboratory testing and process development.